EntryPoint Capital’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$250K Hold
2,761
0.06% 615
2026
Q1
$221K Sell
2,761
-2,456
-47% -$202K 0.06% 602
2025
Q4
$445K Buy
+5,217
New +$428K 0.17% 211
2024
Q4
Sell
-10,400
Closed -$686K 803
2024
Q3
$686K Buy
10,400
+10,388
+86,567% +$755K 0.39% 9
2024
Q2
$1.11K Buy
+12
New +$1.06K ﹤0.01% 1348
2024
Q1
Sell
-1,118
Closed -$85.2K 1526
2023
Q4
$85.2K Buy
+1,118
New +$77.8K 0.08% 459

Other funds holding EW

EntryPoint Capital's EW Position: Q2 2026 in Review

EntryPoint Capital held its Edwards Lifesciences (EW) position steady in Q2 2026 at 2,761 shares worth $250K. The position accounts for 0.06% of the portfolio, ranked #615.

EntryPoint Capital first reported a position in EW in Q4 2023 and has held it in 6 quarters since. The position peaked at $686K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • EntryPoint Capital held 2,761 shares of Edwards Lifesciences worth $250K as of Q2 2026.
  • EntryPoint Capital left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #615 holding.
  • EntryPoint Capital first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 6 quarters since.
  • EntryPoint Capital's Edwards Lifesciences position peaked at $686K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.